Related Experiment Video
Updated: Feb 9, 2026

Induction and Validation of Cellular Senescence in Primary Human Cells
Published on: June 20, 2018
Sodium butyrate induces cellular senescence in neuroblastoma and prostate cancer cells
Abstract:
Cellular senescence leads to an irreversible block of cellular division capacity both in cell culture and in vivo. The induction of an irreversible cell cycle arrest is very useful for treatment of cancer. Histone deacetylases (HDACs) are considered as therapeutic targets to treat cancer patients. HDAC inhibitors repress cancer growth and are used in various clinical trials. Here, we analyzed whether sodium butyrate (NaBu), an inhibitor of class I and II HDACs, induces cellular senescence in neuroblastoma and prostate cancer (PCa) including an androgen-dependent as well as an androgen-independent human PCa cell line. We found that the HDAC inhibitors NaBu and valproic acid (VPA) induce cellular senescence in tumor cells. Interestingly, also an inhibitor of SIRT1, a class HDAC III, induces cellular senescence. Both neuroblastoma and human prostate cancer cell lines express senescence markers, such as the Senescence Associated-β-galactosidase (SA-β-Gal) and Senescence Associated Heterochromatin Foci (SAHF). Furthermore, NaBu down-regulates the proto-oncogenes c-Myc, Cyclin D1 and E2F1 mRNA levels. The mRNA level of the cell cycle inhibitor p16 remains unchanged whereas that of the tumor suppressor p21 is strongly up-regulated. Interestingly, NaBu treatment robustly increases reactive oxygen species (ROS) levels. These results indicate an epigenetic regulation and an association of HDAC inhibition and ROS production with cellular senescence. The data underline that tumor cells can be driven towards cellular senescence by HDAC inhibitors, which may further arise as a potent possibility for tumor suppression.
Insights
Histone deacetylase (HDAC) inhibitors like sodium butyrate (NaBu) induce cellular senescence, a cell division arrest, in cancer cells. This epigenetic regulation, linked to reactive oxygen species (ROS), offers a promising avenue for tumor suppression.
Area of Science:
- Epigenetics
- Cancer Biology
- Cellular Senescence
Background:
- Cellular senescence irreversibly blocks cell division, a valuable mechanism for cancer treatment.
- Histone deacetylases (HDACs) are key therapeutic targets in oncology, with HDAC inhibitors showing promise in clinical trials.
- Understanding novel inducers of senescence is crucial for developing new anti-cancer strategies.
Purpose of the Study:
- To investigate whether sodium butyrate (NaBu), a class I and II HDAC inhibitor, induces cellular senescence in neuroblastoma and prostate cancer (PCa) cell lines.
- To explore the effects of other HDAC inhibitors, including a SIRT1 inhibitor, on tumor cell senescence.
- To elucidate the molecular mechanisms underlying HDAC inhibitor-induced senescence, focusing on gene expression and reactive oxygen species (ROS) production.
Main Methods:
- Treatment of neuroblastoma and human prostate cancer cell lines (androgen-dependent and independent) with HDAC inhibitors (NaBu, valproic acid (VPA), and a SIRT1 inhibitor).
- Assessment of cellular senescence markers, including Senescence-Associated β-galactosidase (SA-β-Gal) and Senescence-Associated Heterochromatin Foci (SAHF).
- Analysis of mRNA levels for proto-oncogenes (c-Myc, Cyclin D1, E2F1), cell cycle inhibitors (p16), and tumor suppressors (p21).
- Measurement of reactive oxygen species (ROS) levels following NaBu treatment.
Main Results:
- Both NaBu and VPA, HDAC inhibitors, effectively induced cellular senescence in tested tumor cell lines.
- A SIRT1 inhibitor also triggered cellular senescence, indicating a role for class III HDACs.
- Senescence markers (SA-β-Gal, SAHF) were expressed in neuroblastoma and prostate cancer cells.
- NaBu downregulated c-Myc, Cyclin D1, and E2F1 mRNA, while upregulating p21 and leaving p16 unchanged.
- NaBu treatment significantly increased ROS levels in tumor cells.
Conclusions:
- HDAC inhibitors, including NaBu, are potent inducers of cellular senescence in various cancer types.
- The induction of senescence by HDAC inhibitors involves epigenetic modifications and is associated with increased ROS production.
- Targeting HDACs represents a viable strategy for cancer treatment by promoting tumor cell senescence and suppression.
Related Concept Videos
Replicative Cell Senescence
Mechanisms of Retrovirus-induced Cancers
Regulation of Sodium and Potassium
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
Roles of Electrolytes: Sodium and Potassium
Induced Pluripotent Stem Cells
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...

